Full-Time
Posted on 9/24/2025
Data-driven medication management for providers
$200k - $220k/yr
San Francisco, CA, USA
In Person
Arine provides a data-driven platform for medication management in healthcare. It analyzes patient health data to offer personalized MTM, medication intelligence, and optimization through a subscription for providers, insurers, and health plans. The goal is to improve patient outcomes while reducing costs, by ensuring safe and effective medication use for older adults and those with complex regimens. It differentiates itself by focusing on personalized, evidence-based MTM and measurable care-quality improvements like CAHPS and Star ratings.
Company Size
201-500
Company Stage
Series C
Total Funding
$70M
Headquarters
San Francisco, California
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Professional Development Budget
Arine, a San Francisco, CA-based AI-driven medication intelligence company, raised $30M in Series C funding.
Arine, a leader in AI-driven medication optimization, announced a $30 million Series C funding round led by Town Hall Ventures, with participation from Kaiser Permanente Ventures. This brings Arine's total funding to $66 million. The funds will help Arine expand its platform's capabilities, focusing on specialty pharmacy management and AI innovation to enhance patient care and cost savings. Arine has achieved over 10% cost savings and 40% reduction in hospitalizations.
/PRNewswire/ -- Today Arine, the leader in AI-driven medication intelligence, announced a Series C funding round. Town Hall Ventures, known for backing...
- Arine, the leader in AI-driven medication intelligence announced it has closed a $30M Series C funding round led by Town Hall Ventures, with participation from Kaiser Permanente Ventures and other existing investors.
Yoona Kim, Founder CEO at ArineAs ultra-fast prescription delivery services reshape medication access, healthcare providers face an urgent challenge: balancing patient convenience with medication safety. With 1 in 5 adults using five or more prescription drugs and medication-related problems consuming 1 in 6 healthcare dollars ($528B annually), the stakes are high.In this interview, Yoona Kim, CEO of healthcare AI company Arine discusses how the evolution of prescription delivery services, while improving access, may inadvertently contribute to dangerous polypharmacy and medication mismanagement. She comments on the critical challenges facing healthcare providers, from fragmented medication tracking to rapidly evolving drug knowledge, and explores how AI-powered solutions can help ensure safe, effective medication management in an increasingly automated healthcare landscape.What are the potential benefits and risks of ultra-fast prescription delivery services like Amazon Pharmacy’s same-day delivery? How can these services impact patient access to medications and adherence to treatment plans?Yoona Kim, Founder CEO at Arine: Ultra-fast prescription delivery services like Amazon Pharmacy’s same-day delivery offer clear benefits to patients, particularly those with acute health needs. Instead of having to pick up medication from the pharmacy – while potentially feeling under the weather – patients can have medications delivered straight to their door within hours. It’s easy to see why this level of convenience is appealing, especially as we grow accustomed to rapid delivery in other areas of our lives, such as grocery shopping.However, this convenience comes with considerable risks in our already fragmented healthcare ecosystem. To start, it complicates providers’ ability to track a patient’s medications